Functional consequences of germline mutations in a novel non-RET medullary thyroid cancer susceptibility gene

Read, Martin; Smith, Joel; Smith, Vicki; Bosseboeuf, Emy; Wake, Naomi; Watsonson, John; Wallis, Yvonne; Maher, Eamonn; McCabe, Christopher; Woodward, Emma

DOI:
10.1530/endoabs.38.OC5.1
OC4.4 Hyperinsulinaemia due to inhibition of 5α-reductases is ameliorated by liver-selective glucocorticoid receptor antagonist in diet-induced obesity

Tracy C S Mak, Dawn E W Livingstone, Brian R Walker & Ruth Andrew University of Edinburgh, Edinburgh, UK.

Background
5α-reductase 1 (5αR1) metabolises steroids such as glucocorticoids and androgens, and is highly expressed in murine liver. Genetic disruption of 5αR1 leads to adverse metabolic changes in mice. We hypothesised that dutasteride, a 5αR inhibitor, induces insulin resistance in mice, as in humans, and this effect is underpinned by increased hepatic glucocorticoid action; an experimental paradigm was set up using A-348441, a liver-selective glucocorticoid receptor (GR) antagonist, and then utilised to assessed the contribution of increased hepatic glucocorticoid action to the metabolic consequences of dutasteride.

Methods
C57BL6/j male mice (n = 8–15/group; age 12 weeks) were given high fat (HF), HF with A-348441 (KarloBio), HF + dutasteride (Dut), or HF + Dut + A-348441 diet for 4 weeks. Glucose tolerance tests (GTT) were performed at week 3, with mice cued at week 4. Plasma insulin and corticosterone were measured by ELISA and plasma glucose spectrophotometrically. Data are mean ± S.E.M., *P < 0.05 vs HF diet and †P < 0.05 vs HF + Dut diet.

Results
Plasma corticosterone concentrations were not changed by A-348441, supporting liver-selective GR antagonism. A-348441 improved metabolic health of mice receiving a HF diet, preventing HF-induced bodyweight gain (34.3 ± 0.5 g vs 31 ± 0.8 g†, and total white adipose depot weight (2.64 ± 0.3 g vs 1.58 ± 0.1 g†), and attenuating HF-induced elevations in fasting plasma insulin, fasting glucose and insulin response to GTT (lowered by 52%, 25%, and 44% respectively). Inhibition of 5αR with dutasteride impaired insulin sensitivity, with increased insulin response to GTT but did not change body weight, total adipose depot weight, fasting insulin, fasting glucose, or glucose response to GTT; A-348441 reduced this hyperinsulinaemia (235.9 ± 17 mg/dl per min vs 329.3 ± 16 mg/dl per min vs 198.4 ± 25 mg/dl per min). Conclusions
Liver-specific GR antagonist ameliorates the metabolic consequences of acute diet-induced obesity. Hyperinsulinaemia caused by inhibition of 5αR was ameliorated by A-348441, suggesting that hepatic glucocorticoid action plays a substantial role in metabolic dysfunction caused by 5αR inhibition. Moreover, targeting hepatic GR may be beneficial in maintaining metabolic homeostasis in diet-induced obesity.

DO: 10.1530/endoabs.38.OC4.4

OC4.5 Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

Chioma Izi-Engebayel1, Victoria Salem1, Rajveer Atkar1, Christopher Coello2, David Thomas1, Alexander Comninos1, Adam Buckley2, Eugenii Rabine2, Roger Gunn3, Tricia Tan3, Stephen Bloom4 & Waljit Dhillo1

1Section of Investigative Medicine, Imperial College London, London, UK; 2Imanova Imaging Centre, London, UK; 3Department of Computing, Imperial College London, London, UK.

Background
Obesity is a global health concern. Elevating energy expenditure (EE) would be a highly effective treatment approach to treat obesity but no current drugs can safely achieve this. Cold exposure potently increases EE through brown adipose tissue (BAT) thermogenesis in humans. Glucagon elevates EE via BAT in rodents but the mechanism in humans is unknown. We investigated for the first time the mechanism in humans.

Methods
Eleven volunteers underwent measurement of EE using an indirect calorimeter at the start and end of three interventions: i) cold exposure; ii) control (vehicle) infusion at 23°C; and iii) glucagon infusion at 23 °C. On each visit thermal images of the neck were taken—an increase in temperature is a non-invasive imaging of the neck were taken—an increase in temperature is a non-invasive measure of increased BAT activity. All 11 volunteers also underwent a FDG PET–CT scan with cold exposure. In those in which this confirmed cold-induced BAT activity (n = 8), they had a second PET–CT scan with either vehicle (n = 4) or glucagon (n = 4) infusion (23 °C).

Results
EE rose by 14% with cold exposure and 15% following glucagon infusion (P < 0.05 vs control). BAT deposits identified on the cold scan had significantly (4 ×) higher metabolic activity than on the vehicle or glucagon infusion scans, which were not significantly different from each other. There was a 0.31 °C rise (P < 0.001) in neck temperature on thermal images after cold exposure in the BAT positive cohort but not after glucagon or vehicle infusion.

Conclusions
Glucagon and cold exposure have a similar effect in stimulating energy expenditure but glucagon has no effect on the metabolic activity of classical adult supraclavicular BAT compared with cold exposure. This information is of importance to the development of better targeted and safe treatments designed to combat obesity through upregulation of energy expenditure.

DO: 10.1530/endoabs.38.OC4.5

OC4.6 Cardiac fibrosis and the balance between glucocorticoid and mineralocorticoid receptors signalling

Rachel Richardson1, Emma Batchen1, Howan Darroch1, Kathleen Scullion1, Ewa Roż-Żelinska1, Christopher Kenyon1, Gillian Gray1 & Karen Chapman1

1University of Edinburgh, Edinburgh, UK; 2Newcastle University, Newcastle, UK; 3Imperial College London, London, UK.

Specific variations in the human glucocorticoid receptor (GR) gene associate with increased cardiovascular disease risk. GR signalling is essential for cardiac maturation in utero and adult mice with cardiomyocyte and vascular smooth muscle depletion of GR (SMGRKO mice) have cardiac hypertrophy, fibrosis and impaired function. Intriguingly, levels of left ventricle (LV) mRNA encoding the mineralocorticoid receptor (MR), which is pro-fibrotic in heart, rise postnatally in SMGRKO mice in parallel with the development of cardiac fibrosis. Here, the benefit of MR antagonism in limiting cardiac fibrosis was assessed in SMGRKO mice. SMGRKO mice (generated via SM22α-Cre mediated deletion of GR) and control (Cre−) littermates were treated from birth with vehicle or 20 mg/kg per day spironolactone, an MR antagonist, administered in the drinking water to lactating dams until weaning then to offspring (n = 10–13/group). At 8 weeks of age, hearts were collected for histology and mRNA profiling. Data were analysed by two-way ANOVA with Tukey’s multiple comparisons test.

Heart weight in male SMGRKO mice was higher than controls irrespective of spironolactone treatment (P < 0.01). Interestingly, spironolactone modestly reduced heart weight in both genotypes (P < 0.05). PicroSirius Red staining showed greater collagen levels in LV of SMGRKO mice (P < 0.001); spironolactone treatment reduced the magnitude of this genotypic difference. Although spironolactone did not prevent the increase in LV levels of mRNA encoding MR or pro-fibrotic factors (connective tissue growth factor, collagen1α2 and collagen3α1) in SMGRKO mice, it did attenuate collagen1α2 mRNA increases (P < 0.05).

In conclusion, the modulatory effects of spironolactone on pro-fibrotic signalling suggest that elevated MR contributes to the pro-fibrotic cardiac phenotype discovered in SMGRKO mice. Consequently, MR antagonism may benefit individuals with particular variants of the GR gene. Spironolactone effects on heart weight indicate a role for MR in early life cardiac growth and SMGRKO mice are, potentially, a useful new model to investigate MR-dependent cardiac fibrosis.

DO: 10.1530/endoabs.38.OC4.6

Thyroid and parathyroid

OC5.1 Functional consequences of germline mutations in a novel non-RET medullary thyroid cancer susceptibility gene

Martin Read1, Joel Smith1, Vicki Smith1, Emu Bosseboue2, Naomi Wake1, John Watkinson3 & Yvonne Wallis1

1Centre for Endocrinology, Diabetes and Metabolism, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; 2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 3Department of Medical Genetics, University of Birmingham, University of Birmingham, Birmingham, UK.

Whilst the majority of familial medullary thyroid cancer (MTC) is caused by germline mutations of the RET proto-oncogene, there are families and individuals
with predisposition to MTC in whom no RET mutation has been identified (non-RET MTC). Recently, we identified novel mutations in a single gene termed MTC2 in non-RET MTC individuals by whole exome sequencing. The precise role of these MTC2 germline mutations in MTC tumorigenesis is however unclear. Here, we examined the functional consequences of MTC2 mutants V128L and G318Afs*22 to determine their roles in MTC. Luciferase (LUC) reporter assays showed that MTC2-V128L retained transcriptional activity with a significant increase in LUC activity in response to steroid hormone receptor-agonist DPN in HCT116 (3.7-fold; P = 0.001) and MCF-7 (1.8-fold; P < 0.005) cells. In contrast, MTC2-G318Afs*22 was incapable of inducing LUC activity in either cell line (P = NS). Furthermore, MTC2-G318Afs*22 failed to inhibit ERα-driven luciferase activity in response to either 17β-estradiol (E2) or ERα-agonist PPT, or restrain ERα-driven proliferation of MCF7 cells (P = NS compared to ERα alone). In contrast, WT MTC2 and MTC2-V128L inhibited ERα-driven LUC activity (> 60%; P < 0.01) and cell proliferation (> 30%; P < 0.05). As RET expression is known to be stimulated by oestrogen, we then determined the influence of MTC2 mutants on RET in E2- and PPT-treated HCT116 cells. In contrast to WT MTC2, MTC2-G318Afs*22 was unable to oppose ERα-stimulation of the RET proto-oncogene in both the mRNA and protein level (P = NS compared to ERα alone). Treatment with anti-oestrogen 4-hydroxytamoxifen was however capable of inhibiting E2-induced RET mRNA expression in cells with MTC2-G318Afs*22. Together these data indicate an emerging role for MTC2 as a novel susceptibility gene in non-RET MTC development, especially as MTC2 mutant G318Afs*22 was associated with higher RET levels. These results also suggest that anti-oestrogens might represent a promising therapeutic strategy for MTC individuals with defective MTC2.

OC5.3

Use of 11C-methionine PET to localise parathyroid adenoma/hyperplasia: a single centre experience
Ben Challis1, Ziauddin Saad1, H K Cheow1, John Buscombe1 & Helen Simpson1
1Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 2University of Cambridge, Cambridge, UK.

Introduction
It is established practice to localise parathyroid lesions preoperatively using ultrasound (US) and sestaMIBI (MIBI). Whilst these imaging techniques have good sensitivity/specify, there are patients in which imaging does not localise a parathyroid lesion. 11C-Methionine PET (MET PET) is an imaging modality where 11C-methionine, a radioactive tracer, is taken up at sites of protein/peptide synthesis and has been demonstrated to be effective in localising parathyroid lesions. We therefore investigated the clinical utility of this imaging technique at our centre.

Methods
All patients had biochemistry prior to imaging thought to be consistent with primary hyperparathyroidism. Criteria to undergo PET imaging were inability of conventional imaging to identify a parathyroid lesion, potential intrathyroidal parathyroid lesion, and three patients where mediastinal disease was suspected. Twenty patients underwent MET PET over an 18-month period.

Results
MET PET identified a parathyroid lesion in 14/20 patients. Three out of three of these were demonstrated to be mediastinal lesions, leading to a parathyroid adenoma being successfully resected by sternotomy. 11/20 demonstrated disease in the neck. Of these 3/11 parathyroid lesions were very deep in the neck adjacent to vertebrae/oesophagus and not seen with US/sestaMIBI. In 2/11 patients MET PET demonstrated intrathyroidal parathyroid lesions and patients underwent hemithyroidectomy. All parathyroid lesions were confirmed on histology (13 adenoma and one hyperplasia). Of the 6/20 who had negative imaging, one now has a diagnosis of sarcoidosis with elevated 1,25-dihydroxycholecalciferol, one underwent bilateral neck exploration and histology demonstrated parathyroid hyperplasia. The remaining four patients are still being investigated with working diagnoses of PBI in three patients.

Discussion
MET PET is a useful additional functional imaging technique when conventional imaging fails to localise a lesion, where mediastinal disease is suspected or intrathyroidal disease needs confirmation. This can particularly helpful when deciding to refer patients for major surgery.

DOI: 10.1530/endoabs.38.OC5.3

OC5.4

A novel modulator of cellular invasion and metastasis in endocrine cancer
Rachel Watkins1, Waraporn Imruetaicharoenchoke1, Neil Sharma1, Erica Gentilini2, Emy Bosseboeuf1, Perkin Kwan1, Rachel Fletcher1, Hisham Mehanna1, Kristien Boelaert1, Martin Read1, Vicki Smith1 & Christopher McCabe1
1University of Birmingham, Birmingham, UK; 2University of Ferrara, Ferrara, Italy.

Metastasis is a multistep process responsible for the majority of endocrine cancer deaths. Central to the ability of cells to move is the recruitment of actin fibres at the periphery of the cell by key proteins, especially the cortical actin binding protein cortactin. A full understanding of cortactin function is required in order to address metastatic cell activity within endocrine cancer. We used IP-MS to discover protein binding partners, and now identify the proto-oncogene PBF as a new functional binding partner of cortactin, whose expression has recently been correlated with thyroid and breast cancer metastasis, and with colon cancer extra-mural vascular invasion. We show that cortacin and PBF interact and co-localise through immunofluorescence and Proximity Ligation Assays, and that this occurs within or close to the plasma membrane, and preferentially at the leading edge of migrating cells. Oncogenic expression of PBF induced potent cell invasion and migration in thyroid TPC-1 (P = 0.01), breast MCF-7 (P < 0.001) and colorectal HCT116 cells (P < 0.001), which was entirely abrogated by the knockdown of cortactin expression. In n = 43 matched papillary thyroid cancers, cortactin was significantly upregulated at the mRNA (P = 0.022) and protein (P = 0.045) levels, particularly in more aggressive tumours, and significantly correlated with PBF expression. We also demonstrate the interaction between PBF and cortactin through co-immunoprecipitation assays and reveal that artificially targeting PBF to the plasma membrane results in increased cortactin binding, entirely blocking endogenous cellular invasion. Thus, we identify a new modulator of cortactin

Endocrine Abstracts (2015) Vol 38